Keyword Analysis & Research: abt 263
Keyword Research: People who searched abt 263 also searched
Search Results related to abt 263 on Search Engine
-
Navitoclax - Wikipedia
https://en.wikipedia.org/wiki/Navitoclax
WebClinical trials. Antisclerotic. References. Navitoclax (previously ABT-263) is an experimental orally active anti- cancer drug, which is a Bcl-2 inhibitor similar in action to obatoclax. [1] [2] Mechanism of action. Navitoclax inhibits not only Bcl-2, but also Bcl-X L and Bcl-w proteins. [3] .
DA: 50 PA: 59 MOZ Rank: 55
-
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients …
https://ascopubs.org/doi/10.1200/JCO.21.02188
WebFeb 18, 2022 · Navitoclax (ABT-263) is an orally bioavailable, small-molecule BCL-2 homology 3 mimetic that binds with high affinity (K i ≤ 1 nmol/L) to prosurvival BCL-2 family proteins (BCL-X L, BCL-2, and BCL-W), disrupting interactions with proapoptotic factors such as BIM, thereby promoting the apoptosis of malignant cells (Data Supplement, …
DA: 35 PA: 47 MOZ Rank: 85
-
ABT-263 (Navitoclax) | Cell Signaling Technology
https://www.cellsignal.com/products/activators-inhibitors/abt-263-navitoclax/79381
WebABT-263 (Navitoclax) is a potent and orally bioavailable Bcl-2 family inhibitor. This small molecule mimetic of BH3 domains specifically binds to Bcl-2, Bcl-xL, and Bcl-W with a K i value of less than 1 nM (1). ABT-263 (Navitoclax) has been shown to have antitumor effects on small cell lung cancer (SCLC) xenograft models, resulting in complete ...
DA: 37 PA: 32 MOZ Rank: 11
-
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor
https://pubmed.ncbi.nlm.nih.gov/18451170/
WebMay 1, 2008 · Here we report the biological properties of ABT-263, a potent, orally bioavailable Bad-like BH3 mimetic (K (i)'s of <1 nmol/L for Bcl-2, Bcl-xL, and Bcl-w). The oral bioavailability of ABT-263 in preclinical animal models is 20% to …
DA: 37 PA: 24 MOZ Rank: 35
-
Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven ... - Nature
https://www.nature.com/articles/s41419-021-03971-7
WebJul 13, 2021 · Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy | Cell Death & Disease. Article. Open access. Published: 13 July 2021. Bcl-2/Bcl-xL...
DA: 63 PA: 84 MOZ Rank: 48
-
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family …
https://ascopubs.org/doi/10.1200/JCO.2010.31.6208
WebJan 31, 2011 · Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. JCO 29 , 909-916 (2011). DOI: 10.1200/JCO.2010.31.6208
DA: 68 PA: 91 MOZ Rank: 59
-
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
https://aacrjournals.org/cancerres/article/68/9/3421/543391/ABT-263-A-Potent-and-Orally-Bioavailable-Bcl-2
WebMay 1, 2008 · A major limitation of ABT-737 is that it is not orally bioavailable, which would limit chronic single agent therapy and flexibility to dose in combination regimens. Here we report the biological properties of ABT-263, a potent, orally bioavailable Bad-like BH3 mimetic (K i 's of <1 nmol/L for Bcl-2, Bcl-xL, and Bcl-w). The oral bioavailability ...
DA: 32 PA: 12 MOZ Rank: 43
-
Assessment of ABT-263 activity across a cancer cell line ... - PNAS
https://www.pnas.org/doi/10.1073/pnas.1411848112
WebMar 3, 2015 · Abstract. BH3 mimetics such as ABT-263 induce apoptosis in a subset of cancer models. However, these drugs have shown limited clinical efficacy as single agents in small-cell lung cancer (SCLC) and other solid tumor malignancies, and rational combination strategies remain underexplored.
DA: 49 PA: 20 MOZ Rank: 16
-
The Bcl-2 Family Inhibitor ABT-263 Shows Significant Anti-Tumor
https://ashpublications.org/blood/article/108/11/825/130251/The-Bcl-2-Family-Inhibitor-ABT-263-Shows
WebNov 16, 2006 · ABT-263 is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins with a K. of ≤ 1 nM against Bcl-2, Bcl-X L, and Bcl-w.
DA: 20 PA: 8 MOZ Rank: 40
-
An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, …
https://ashpublications.org/blood/article/112/11/3177/60030/An-Ongoing-Phase-1-Study-of-ABT-263
WebNov 16, 2008 · ABT-263 is a novel, orally bioavailable and active small molecule Bcl-2 family protein inhibitor with predictable and manageable toxicity and anti-tumor activity in relapsed or refractory CLL patients. The thrombocytopenia is predictable and manageable.
DA: 8 PA: 81 MOZ Rank: 20
-
Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977433/
WebFeb 2, 2023 · Treatment with ABT-263 induced fibroblast apoptosis, decreased fibroblast numbers, and reduced lung collagen levels, radiographic disease, and histologically evident fibrosis. Our studies provide insight into how fibroblasts gain resistance to apoptosis and become sensitive to the therapeutic inhibition of antiapoptotic proteins.
DA: 99 PA: 1 MOZ Rank: 80
-
Navitoclax (ABT-263) | 99.9%(HPLC) | In Stock | Bcl-2 inhibitor
https://www.selleckchem.com/products/ABT-263.html
WebNavitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2. Navitoclax (ABT-263) Chemical Structure. CAS: 923564-51-6.
DA: 100 PA: 58 MOZ Rank: 46
-
Synergistic activity of ABT-263 and ONC201/TIC10 against solid …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906082/
WebJan 15, 2023 · ABT-263 is a small molecule that targets the intrinsic apoptotic pathway. It induces tumor cell death by directly binding to Bcl-xL and Bcl-2 and blocking their anti-apoptotic function. The ABT-263 targeting of Bcl-xL has been found to cause an on-target dose-dependent thrombocytopenia in vivo and in the clinic [ 3 - 5 ].
DA: 4 PA: 5 MOZ Rank: 100
-
Frontiers | The Senolytic Drug Navitoclax (ABT-263) Causes …
https://www.frontiersin.org/articles/10.3389/fcell.2020.00354/full
WebNavitoclax (also known as ABT-263) is a chemotherapeutic drug reported to effectively clear senescent hematopoietic stem cells, muscle stem cells, and mesenchymal stromal cells in previous studies, but its in vivo effects on bone mass had not yet been reported.
DA: 47 PA: 77 MOZ Rank: 23
-
The Bcl-2 Family Inhibitor ABT-263 Shows Significant but …
https://ashpublications.org/blood/article/108/11/1107/119493/The-Bcl-2-Family-Inhibitor-ABT-263-Shows
WebNov 16, 2006 · ABT-263 is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins with a K. of ≤ 1 nM against Bcl-2, Bcl-X L, and Bcl-w. Potent cytotoxic effects have been demonstrated against small cell lung carcinomas and lymphomas (EC 50 of less than 500 nM in vitro against numerous cell lines).
DA: 32 PA: 15 MOZ Rank: 82
-
A phase IIa study of ABT-263 in patients with relapsed small-cell …
https://ascopubs.org/doi/10.1200/jco.2010.28.15_suppl.7046
WebMay 20, 2010 · Background: ABT-263, a novel BH3 mimetic, binds with high affinity (Ki ≤ 1 nM) and inhibits multiple antiapoptotic Bcl-2 proteins. SCLC is an aggressive cancer, which constitutes nearly 15% of all lung neoplasms in the United States and has few effective treatment options after first-line therapy. SCLC tumors frequently overexpress Bcl-2.
DA: 48 PA: 49 MOZ Rank: 7
-
ABT-263 induces G 1/G 0-phase arrest, apoptosis and autophagy ... - PubMed
https://pubmed.ncbi.nlm.nih.gov/28713162/
WebABT-263 (Navitoclax), a novel BH3 mimetic and orally bioavailable Bcl-2 family inhibitor with high affinity for Bcl-xL, Bcl-2 and Bcl-w has entered clinical trials for cancer treatment. But the anticancer mechanisms of ABT-263 have not been fully elucidated.
DA: 11 PA: 46 MOZ Rank: 99
-
APExBIO - ABT-263 (Navitoclax) | Potent Bcl-2 family inhibitor
https://www.apexbt.com/abt-263-navitoclax.html
WebABT-263 is a small molecular with the formula of C47H55ClF3N5O6S3 and Molecular Weight of 974. As a Bad-like Bh3 minetic, ABT-263 binds to Bcl-2 family proteins Bcl-2, Bcl-xl and Bcl-w, disrupts the interaction between Bcl-2/Bcl-xl /Bcl-w and pro-apoptotic proteins such as Bim, Bad and Bak, which trigger the caspases-initiated cell death ...
DA: 16 PA: 86 MOZ Rank: 16
-
Navitoclax (ABT-263) | Bcl-2 Inhibitor | MedChemExpress
https://www.medchemexpress.com/navitoclax.html
WebNavitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-x L, Bcl-2 and Bcl-w, with a K of less than 1 nM. For research use only. We do not sell to patients. Navitoclax Chemical Structure. CAS No. : 923564-51-6.
DA: 2 PA: 3 MOZ Rank: 74
-
Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed …
https://ashpublications.org/blood/article/112/11/2108/57878/Phase-1-Study-of-ABT-263-a-Bcl-2-Family-Inhibitor
WebNov 16, 2008 · ABT-263 is a novel, orally bioavailable BH3 mimetic that binds with high affinity (K. ≤1nM) and inhibits multiple antiapoptotic Bcl-2 family proteins. ABT-263 displays potent mechanism-based activity (EC 50 ≤ 1μM) against human lymphoid and small cell lung cancer cell-lines.
DA: 60 PA: 59 MOZ Rank: 87
-
Statute | Kansas State Legislature
http://kslegislature.org/li_2018/b2017_18/statute/021_000_0000_chapter/021_054_0000_article/021_054_0026_section/021_054_0026_k/
Web21-5426. Human trafficking; aggravated human trafficking. (a) Human trafficking is: (1) Except as provided in subsection (b) (4) and (5), the intentional recruitment, harboring, transportation, provision or obtaining of a person for labor or services, through the use of force, fraud or coercion for the purpose of subjecting the person to ...
DA: 81 PA: 33 MOZ Rank: 3
-
ABC Forms by Form Number - Kansas Department of Revenue
https://www.ksrevenue.gov/abcforms.html
WebABC-22 ABC Liquor License or Permit Business Name and/or Address Change Form. ABC-41 ABC Open Records Request. ABC-60 Law Enforcement Notification. ABC-61 BYOB Report. ABC-73 Monthly Report of On-Premise Sales. ABC-160 Irrevocable Consent to Jurisdiction. ABC-170 Keg Registration Form. ABC-171 Keg Tag Order Forms.
DA: 91 PA: 15 MOZ Rank: 26
-
Session of 2023 SENATE BILL No. 263 - Kansas Legislature
http://kslegislature.org/li/b2023_24/measures/documents/sb263_00_0000.pdf
WebSENATE BILL No. 263. By Committee on Assessment and Taxation. 2-16. AN ACT concerning property taxation; relating to appraiser directives; requiring appraiser directives be established by rules and regulations; 4 3 amending K.S.A. 2022 Supp. 79-505 and repealing the existing section. 5 Be it enacted by the Legislature of the State of Kansas:
DA: 36 PA: 76 MOZ Rank: 62
